Human Papilloma Virus Immunisations | OMICS International| Journal Of Community Medicine And Health Education

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Human Papilloma Virus Immunisations

Vaccination with HPV 16/18 L1 vaccine provides no benefit for women with pre-existing infection and may leave them more susceptible to other oncogenic HPV types therefore cervical cancer should be ruled out through Pap smear before HPV vaccine is administered. Though women could be infected by HPV at any age, infections at a very young age could be dangerous because they have more time-line to cause damage that eventually leads to cancer. Despite vaccination, womenstill need to continue cervical cancer screening on account of the risk exposure to other oncogenic HPV types and the unknown duration of the anti-HPV immunity. Odetola TD, Ekpo K (2012) Nigerian Women’s Perceptions about Human Papilloma Virus Immunisations. J Community Med Health Educ 2:191
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on May, 2021